Search results
Results from the WOW.Com Content Network
[9] [10] It can also reduce DHT levels in the prostate by 97 to 99% in men with prostate cancer. [11] [12] Epristeride (brand names Aipuliete, Chuanliu) is marketed in China for the treatment of benign prostatic hyperplasia. [13] [14] [15] However, it can only decrease circulating DHT levels by about 25 to 54%. [16]
Alpha 1 blockers cause vasodilation by relaxing smooth muscles that control blood vessel diameter, leading to lower blood pressure. [1] FDA-approved uses of these drugs include treating conditions like benign prostatic hyperplasia, hypertension, pheochromocytoma, extravasation management, and reversal of local anesthesia.
Patients who need alpha blockers for BPH, but have a history of hypotension or postural heart failure, should use these drugs with caution, as it may result in an even greater decrease in blood pressure or make heart failure even worse. [35] [36] The most compelling contraindication is urinary incontinence and overall fluid retention.
Beta blockers are known primarily for their reductive effect on heart rate, although this is not the only mechanism of action of importance in congestive heart failure. [17] Beta blockers, in addition to their sympatholytic β 1 activity in the heart, influence the renin–angiotensin system at the kidneys.
Female ejaculate may result from sexual activity for some women, especially during orgasm. [3] [4] In addition to PSA and acid phosphatase, Skene's gland fluid contains high concentrations of glucose and fructose. [3] In an amount of a few milliliters, fluid is secreted from these glands when stimulated from inside the vagina.
The choice between the drugs is to a large degree determined by the characteristics of the patient being prescribed for, the drugs' side effects, and cost. Most drugs have other uses; sometimes the presence of other symptoms can warrant the use of one particular antihypertensive. Examples include: Age can affect the choice of medications.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
The prostatic fluid is expelled in the first part of ejaculate, together with most of the sperm, because of the action of smooth muscle tissue within the prostate. In comparison with the few spermatozoa expelled together with mainly seminal vesicular fluid, those in prostatic fluid have better motility , longer survival, and better protection ...